surmount-1 tirzepatide weight loss percent nejm 2022 📊 Semaglutide 2.4mg: −13.7% (SURMOUNT-5 head-to-head), 📊 15mg: −20.2% weight loss (same trial, 2025), 📊 Retatrutide 12mg: −28.7% weight loss (TRIUMPH-4, Phase 3, Dec Read now: The SURPASS-EARLY trial

These trials are among the largest peptide weight loss studies ever conducted, with thousands of participants across multiple continents and diverse populations

It has the active ingredient semaglutide

This may be because most participants were normotensive at baseline

These individuals also recorded improvements in waist size, blood pressure, blood sugar, and cholesterolfactors closely tied to obesity-related risks

Body composition Researched in rodent studies on adipocyte size and lean-versus-fat mass

It is an umbrella term covering damage to peripheral nerves, the vast network of fibers that carry signals between your brain, spinal cord, and the rest of your body